Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors as antimalarial agents

References

• Vyas VK, Bhati S, Patel S, et al. Structure- and ligand-based drug design methods for the modeling of antimalarial agents: a review of updates from 2012 onwards. J Biomol Struct Dynamics. 2022;40(20):10481–10506. doi: 10.1080/07391102.2021.1932598
   PubMed Web of Science ®Google Scholar
• Weiss DJ, Lucas TCD, Nguyen M, et al. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial and temporal modelling study. Lancet. 2019;394(10195):322–331.
   PubMed Web of Science ®Google Scholar
• Escalante AA, Pacheco MA. Malaria molecular epidemiology: an evolutionary genetics perspective. Microbiol Spectr. 2019;7(4). doi: 10.1128/microbiolspec.AME-0010-2019
   PubMed Web of Science ®Google Scholar
• Lou Y, Han X, Kuglstatter A, et al. Structure-based drug design of RN486, a potent and selective bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. J Med Chem. 2015;58(1):512–516.
   PubMed Web of Science ®Google Scholar
• World malaria report 2022. 2022[ Online].
   Google Scholar
• WHO. WHO malaria Policy Advisory Committee (MPAC) 2018; (April):p. 1–18.
   Google Scholar
• Howes RE, Battle KE, Mendis KN, et al. Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95(6 Suppl):15–34.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Yang D-S, Goulbourne CN, et al. Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nat Neurosci. 2022;25(6):688–701.
   PubMed Web of Science ®Google Scholar
• Lubis IND, Wijaya H, Lubis M, et al. Contribution of Plasmodium knowlesi to Multispecies human malaria Infections in North Sumatera, Indonesia. J Infect Dis. 2017;215(7):1148–1155.
   PubMed Web of Science ®Google Scholar
• Ng YL, Lee W-C, Lau Y-L, et al. The impact of geographical variation in Plasmodium knowlesi apical membrane protein 1 (PkAMA-1) on Invasion Dynamics of P. knowlesi. Trop Med Infect Dis. 2023;8(1):56.
   PubMedGoogle Scholar
• Mace KE, Arguin PM, Tan KR. Malaria surveillance — United States, 2015. MMWR Surveill Summ. 2018;67(7):1–28. doi: 10.15585/mmwr.ss6707a1
   PubMed Web of Science ®Google Scholar
• Khan MI, Qureshi H, Bae SJ, et al. Malaria prevalence in Pakistan: a systematic review and meta-analysis (2006–2021). Heliyon. 2023;9(4):e15373.
   PubMed Web of Science ®Google Scholar
• White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383(9918):723–735.
   PubMed Web of Science ®Google Scholar
• Naserrudin NA, Yong PPL, Monroe A, et al. Seeing malaria through the eyes of affected communities: using photovoice to document local knowledge on zoonotic malaria causation and prevention practices among rural communities exposed to Plasmodium knowlesi malaria in Northern Borneo Island. Malaria j. 2023;22(1):166.
   PubMed Web of Science ®Google Scholar
• Fornace KM, Topazian HM, Routledge I, et al. No evidence of sustained nonzoonotic Plasmodium knowlesi transmission in Malaysia from modelling malaria case data. Nat Commun. 2023;14(1):2945.
   PubMed Web of Science ®Google Scholar
• Sutherland CJ. Persistent parasitism: the adaptive biology of malariae and ovale malaria. Trends Parasitol. 2016;32(10):808–819. doi: 10.1016/j.pt.2016.07.001
   PubMed Web of Science ®Google Scholar
• Daniels RF, Deme AB, Gomis JF, et al. Evidence of non-Plasmodium falciparum malaria infection in Kédougou, Sénégal. Malaria j. 2017;16(1):9.
   PubMedGoogle Scholar
• Conroy AL, Datta D, John CC. What causes severe malaria and its complications in children? Lessons learned over the past 15 years. BMC Med. 2019;17(1):52. doi: 10.1186/s12916-019-1291-z
   PubMed Web of Science ®Google Scholar
• Horak P, Auer H, Wiedermann U, et al. Malaria in Austria: a retrospective analysis of malaria cases diagnosed at a reference center in 2010-2020. Wien Klin Wochenschr. 2023;135:1–8.
   Google Scholar
• Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet. 2018;391(10130):1608–1621. doi: 10.1016/S0140-6736(18)30324-6
   PubMed Web of Science ®Google Scholar
• Benelli G, Beier JC. Current vector control challenges in the fight against malaria. Acta tropica. 2017;174:91–96. doi: 10.1016/j.actatropica.2017.06.028
   PubMed Web of Science ®Google Scholar
• Lamptey H, Ofori MF, Kusi KA, et al. The prevalence of submicroscopic Plasmodium falciparum gametocyte carriage and multiplicity of infection in children, pregnant women and adults in a low malaria transmission area in Southern Ghana. Malaria j. 2018;17(1):331.
   PubMedGoogle Scholar
• Zekar L, Sharman T Plasmodium Falciparum malaria StatPearls 2022[Online] 2022.
   Google Scholar
• Meibalan E, Marti M. Biology of malaria transmission. Cold Spring Harb Perspect Med. 2017;7(3):a025452. doi: 10.1101/cshperspect.a025452
   PubMed Web of Science ®Google Scholar
• Milner DA. Malaria Pathogenesis. Cold Spring Harb Perspect Med. 2018;8(1):a025569. doi: 10.1101/cshperspect.a025569
   PubMed Web of Science ®Google Scholar
• Vyas VK, Bhati S, Sharma M, et al. 3D-QSAR-based design, synthesis and biological evaluation of 2,4-disubstituted quinoline derivatives as antimalarial agents. SAR QSAR Environ Res. 2023;34(8):639–659.
   PubMed Web of Science ®Google Scholar
• Pinheiro LCS, Feitosa LM, Silveria FD, et al. Current antimalarial therapies and advances in the development of semi-synthetic artemisinin derivatives. Anais da Academia Brasileira de Ciências. 2018;90(1 suppl 2):1251–1271.
   PubMedGoogle Scholar
• Tse EG, Korsik M, Todd MH. The past, present and future of anti-malarial medicines. Malaria j. 2019;18(1):93. doi: 10.1186/s12936-019-2724-z
   PubMedGoogle Scholar
• Okombo J, Chibale K. Insights into integrated lead generation and target Identification in malaria and tuberculosis drug discovery. Acc Chem Res. 2017;50(7):1606–1616. doi: 10.1021/acs.accounts.6b00631
   PubMed Web of Science ®Google Scholar
• Consalvi S, Tammaro C, Appetecchia F, et al. Malaria transmission blocking compounds: a patent review. Expert Opin Ther Patents. 2022;32(6):649–666. doi: 10.1080/13543776.2022.2049239
   PubMed Web of Science ®Google Scholar
• Wells TNC, RH van H, WC Van V. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14(6):424–442. doi: 10.1038/nrd4573
   PubMed Web of Science ®Google Scholar
• Fonte M, Tassi N, Gomes P, et al. Acridine-based antimalarials—from the very first synthetic antimalarial to Recent developments. Molecules. 2021;26(3):600.
   PubMed Web of Science ®Google Scholar
• Shalini, Kumar S, Gendrot M, et al. Amide tethered 4-aminoquinoline-naphthalimide hybrids: a new class of possible Dual function antiplasmodials. ACS Med Chem Lett. 2020;11(12):2544–2552.
   PubMed Web of Science ®Google Scholar
• Gao X, Bai Y, Sun P, et al. Combined chemical transformation and biological transformation of artemisinin: a facile approach to diverse artemisinin derivatives. Front Chem. 2022;10:1089290. doi: 10.3389/fchem.2022.1089290
   PubMed Web of Science ®Google Scholar
• Zhan W, Li D, Subramanyaswamy SB, et al. Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance. Cell Chem Biol. 2023;30(5):457–469.e11.
   PubMed Web of Science ®Google Scholar
• Quagliata M, Papini AM, Rovero P. Malaria vaccines. Expert Opinion on Therapeutic Patents. Expert Opin Ther Patents. 2023;33(3):169–178. doi: 10.1080/13543776.2023.2190884
   PubMed Web of Science ®Google Scholar
• Bhanot A, Sundriyal S. Physicochemical Profiling and comparison of research Antiplasmodials and advanced stage antimalarials with oral drugs. ACS Omega. 2021;6(9):6424–6437. doi: 10.1021/acsomega.1c00104
   PubMed Web of Science ®Google Scholar
• Boor SVD, Alkema M, Gemert G-JV, et al. Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial. BMC Med. 2023;21(1):137.
   PubMed Web of Science ®Google Scholar
• Walker IS, Rogerson SJ. Pathogenicity and virulence of malaria: sticky problems and tricky solutions. Virulence. 2023;14(1):2150456. doi: 10.1080/21505594.2022.2150456
   PubMed Web of Science ®Google Scholar
• Trager W, Jensen JB. Human Malaria Parasites in Continuous Culture. Science. 1976;193(4254):673–675. doi: 10.1126/science.781840
   PubMed Web of Science ®Google Scholar
• Foquet L, Schafer C, Minkah NK, et al. Plasmodium falciparum liver stage infection and transition to stable blood stage infection in liver-humanized and blood-humanized FRGN KO mice enables testing of blood stage inhibitory antibodies (reticulocyte-binding protein homolog 5) in vivo. Front Immunol. 2018;9: doi: 10.3389/fimmu.2018.00524
   PubMed Web of Science ®Google Scholar
• Mo AX, McGugan G. Understanding the liver-stage biology of malaria parasites: insights to enable and accelerate the development of a highly efficacious vaccine. Am J Trop Med Hyg. 2018;99(4):827–832. doi: 10.4269/ajtmh.17-0895
   PubMed Web of Science ®Google Scholar
• Dorjsuren D, Eastman RT, Wicht KJ, et al. Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites. Sci Rep. 2021;11(1):2121.
   PubMed Web of Science ®Google Scholar
• Valenciano AL, Gomez-Lorenzo MG, Vega-Rodríguez J, et al. In vitro models for human malaria: targeting the liver stage. Trends Parasitol. 2022;38(9):758–774.
   PubMed Web of Science ®Google Scholar
• Posfai D, Maher SP, Roesch C, et al. Plasmodium vivax liver and blood stages recruit the druggable host membrane channel aquaporin-3. Cell Chem Biol. 2020;27(6):719–727.e5.
   PubMed Web of Science ®Google Scholar
• Goswami D, Minkah NK, Kappe SHI. Malaria parasite liver stages. J Hepatol. 2022;76(3):735–737. doi: 10.1016/j.jhep.2021.05.034
   PubMed Web of Science ®Google Scholar
• Phillips MA, Lotharius J, Marsh K, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci, trans med. 2015;7(296). doi: 10.1126/scitranslmed.aaa6645
   Web of Science ®Google Scholar
• Lee RS, Waters AP, Brewer JM. A cryptic cycle in haematopoietic niches promotes initiation of malaria transmission and evasion of chemotherapy. Nat Commun. 2018;9(1):1689. doi: 10.1038/s41467-018-04108-9
   PubMedGoogle Scholar
• Erbland M. Chronic obstructive pulmonary disease and carbohydrate feedings. Ann internal med. 1986;104(6):889–890. doi: 10.7326/0003-4819-104-6-889_2
   PubMed Web of Science ®Google Scholar
• Colomina MT, Peris-Sampedro F. Aluminum and Alzheimer’s disease. Advan in Neurobi. 2017;18:183–197.
   PubMedGoogle Scholar
• Kumar S, Bhardwaj TR, Prasad DN, et al. Drug targets for resistant malaria: Historic to future perspectives. Biomed Pharmacother. 2018;104:8–27. doi: 10.1016/j.biopha.2018.05.009
   PubMed Web of Science ®Google Scholar
• Pinheiro L CS, Feitosa L M, Gandi M O, et al. The development of novel compounds against malaria: quinolines, Triazolpyridines, Pyrazolopyridines and Pyrazolopyrimidines. Molecules. 2019;24(22):4095.
   PubMed Web of Science ®Google Scholar
• Lopes EA, Santos MMM, Mori M. Antimalarial drugs: what’s new in the patents? Expert opinion on therapeutic patents. 2023;33(3):151–168. doi: 10.1080/13543776.2023.2203814
   Google Scholar
• Adigun RA, Malan FP, Balogun MO, et al. Design, synthesis, and in silico-in vitro antimalarial evaluation of 1,2,3-triazole-linked dihydropyrimidinone quinoline hybrids. Struct Chem. 2023. doi: 10.1007/s11224-023-02142-y
   Web of Science ®Google Scholar
• Madu UL, Ogundeji AO, Pohl CH, et al. Primaquine, an antimalarial drug that controls the growth of cryptococcal cells. Journal de mycologie medicale. 2023;33(2):101361.
   PubMed Web of Science ®Google Scholar
• Zorc B, Perković I, Pavić K, et al. Primaquine derivatives: modifications of the terminal amino group. Eur J Med Chem. 2019;182:111640. doi: 10.1016/j.ejmech.2019.111640
   PubMed Web of Science ®Google Scholar
• Antony H, Parija S. Antimalarial drug resistance: An overview. Trop Parasitol. 2016;6(1):30. doi: 10.4103/2229-5070.175081
   PubMedGoogle Scholar
• Singh S, Singh A, Singh M, et al. Modern advancement in the area of antimalarial drug development. Indian J Heterocycl Chem. 2018;28(2):185–194.
   Web of Science ®Google Scholar
• Yadav MK, Tripathi MK, Yadav S. Discovery of novel inhibitors targeting Plasmodium knowlesi dihydrofolate reductase using molecular docking and molecular dynamics simulation. Microbial Pathogenesis. 2021;161(Pt A):105214. doi: 10.1016/j.micpath.2021.105214
   PubMedGoogle Scholar
• Adeel AA, Elnour FAA, Elmardi KA, et al. High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies. Malaria j. 2016;15(1):285.
   PubMedGoogle Scholar
• Yang J, He Y, Li Y, et al. Advances in the research on the targets of anti-malaria actions of artemisinin. Pharmacol Ther. 2020;216:107697. doi: 10.1016/j.pharmthera.2020.107697
   PubMed Web of Science ®Google Scholar
• Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015;520(7549):683–687.
   PubMed Web of Science ®Google Scholar
• Suresh N, Haldar K. Mechanisms of artemisinin resistance in Plasmodium falciparum malaria. Curr Opin Pharmacol. 2018;42:46–54. doi: 10.1016/j.coph.2018.06.003
   PubMed Web of Science ®Google Scholar
• Wang J, Huang Y, Zhao Y, et al. Introduction of F446I mutation in the K13 propeller gene leads to increased ring survival rates in Plasmodium falciparum isolates. Malaria j. 2018;17(1):248.
   PubMedGoogle Scholar
• Intharabut B, Kingston HW, Srinamon K, et al. Artemisinin resistance and stage dependency of parasite clearance in falciparum malaria. J Infect Dis. 2019;219(9):1483–1489.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Coppens I, Mbengue A, et al. Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood. 2018;131(11):1234–1247.
   PubMed Web of Science ®Google Scholar
• Dogovski C, Xie SC, Burgio G, et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol. 2015;13(4):e1002132.
   PubMed Web of Science ®Google Scholar
• Tilley L, Straimer J, Gnädig NF, et al. Artemisinin Action and Resistance in Plasmodium falciparum. Trends Parasitol. 2016;32(9):682–696.
   PubMed Web of Science ®Google Scholar
• Rocamora F, Zhu L, Liong KY, et al. Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. PLOS Pathogens. 2018;14(3):e1006930.
   PubMed Web of Science ®Google Scholar
• Mok S, Ashley EA, Ferreira PE, et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015;347(6220):431–435.
   PubMed Web of Science ®Google Scholar
• Hanboonkunupakarn B, Tarning J, Pukrittayakamee S, et al. Artemisinin resistance and malaria elimination: where are we now? Front Pharmacol. 2022;13: doi: 10.3389/fphar.2022.876282
   PubMed Web of Science ®Google Scholar
• Baker DA, Drought LG, Flueck C, et al. Cyclic nucleotide signalling in malaria parasites. Open Biol. 2017;7(12):170213.
   PubMed Web of Science ®Google Scholar
• Goodman CD, Buchanan HD, McFadden GI. Is the mitochondrion a good malaria drug target? Trends Parasitol. 2017;33(3):185–193. doi: 10.1016/j.pt.2016.10.002
   PubMed Web of Science ®Google Scholar
• Blanshard A, Hine P. Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2021;2021(2). doi: 10.1002/14651858.CD004529.pub3
   Google Scholar
• Komatsuya K, Sakura T, Shiomi K, et al. Siccanin Is a Dual-Target Inhibitor of Plasmodium falciparum Mitochondrial Complex II and Complex III. Pharmaceuticals. 2022;15(7). doi: 10.3390/ph15070903
   Web of Science ®Google Scholar
• Baragaña B, Hallyburton I, Lee MCS, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522(7556):315–320.
   PubMed Web of Science ®Google Scholar
• Hochegger P, Faist J, Seebacher W, et al. New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity. Bioorg Med Chem. 2017;25(7):2251–2259.
   PubMed Web of Science ®Google Scholar
• Ross LS, Fidock DA. Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum. Cell Host Microbe. 2019;26(1):35–47. doi: 10.1016/j.chom.2019.06.001
   PubMed Web of Science ®Google Scholar
• Siqueira-Neto JL, Wicht KJ, Chibale K, et al. Antimalarial drug discovery: progress and approaches. Nat Rev Drug Discov. 2023;22(10):807–826.
   PubMed Web of Science ®Google Scholar
• Aroonsri A, Akinola O, Posayapisit N, et al. Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling. Int J Parasitol. 2016;46(8):527–535.
   PubMed Web of Science ®Google Scholar
• Ittarat W, Pornthanakasem W, Mungthin M, et al. Characterization of Plasmodium knowlesi dihydrofolate reductase-thymidylate synthase and sensitivity to antifolates. Parasitol Int. 2018;67(6):787–792.
   PubMed Web of Science ®Google Scholar
• Chaianantakul N, Sungkapong T, Supatip J, et al. Antimalarial effect of cell penetrating peptides derived from the junctional region of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Peptides. 2020;131:170372. doi: 10.1016/j.peptides.2020.170372
   PubMed Web of Science ®Google Scholar
• Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191–199.
   PubMed Web of Science ®Google Scholar
• Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020;13:4047–4060. doi: 10.2147/IDR.S279433
   PubMed Web of Science ®Google Scholar
• Shang X, Yang C, Morris‐Natschke SL, et al. Biologically active isoquinoline alkaloids covering 2014–2018. Med Res Rev. 2020;40(6):2212–2289.
   PubMed Web of Science ®Google Scholar
• Çapcı A, Herrmann L, Sampath Kumar HM, et al. Artemisinin‐derived dimers from a chemical perspective. Med Res Rev. 2021;41(6):2927–2970.
   PubMed Web of Science ®Google Scholar
• Tople MS, Patel NB, Patel PP, et al. An in silico-in vitro antimalarial and antimicrobial investigation of newer 7-chloroquinoline based Schiff-bases. J Mol Struct. 2023;1271:134016. doi: 10.1016/j.molstruc.2022.134016
   Web of Science ®Google Scholar
• Reis RAG, Calil FA, Feliciano PR, et al. The dihydroorotate dehydrogenases: Past and present. Arch Biochem Biophys. 2017;632:175–191. doi: 10.1016/j.abb.2017.06.019
   PubMed Web of Science ®Google Scholar
• Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in Plasmodium. Nature Rev Microbiol. 2018;16(3):156–170. doi: 10.1038/nrmicro.2017.161
   PubMed Web of Science ®Google Scholar
• White J, Dhingra SK, Deng X, et al. Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265. ACS Infect Dis. 2019;5(1):90–101.
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Casapia M, Chuquiyauri R, et al. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. Lancet Infect Dis. 2018;18(8):874–883.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Lotharius J, Rückle T, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis. 2017;17(6):626–635.
   PubMed Web of Science ®Google Scholar
• Sulyok M, Rückle T, Roth A, et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017;17(6):636–644.
   PubMed Web of Science ®Google Scholar
• Phillips MA, White KL, Kokkonda S, et al. A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria. ACS Infect Dis. 2016;2(12):945–957.
   PubMed Web of Science ®Google Scholar
• Phillips M A, Rathod P K. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord. 2010;10(3):226–239. doi: 10.2174/187152610791163336
   PubMedGoogle Scholar
• Vyas K, Ghate M V. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini-Rev Med Chem. 2011;11(12):1039–1055. doi: 10.2174/138955711797247707
   PubMed Web of Science ®Google Scholar
• Vyas VK, Parikh H, Ghate M. 3D QSAR studies on 5-(2-methylbenzimidazol-1-yl)-N-alkylthiophene-2-carboxamide derivatives as P. falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. Med Chem Res. 2013;22(5):2235–2243. doi: 10.1007/s00044-012-0216-6
   Web of Science ®Google Scholar
• Gehlot P, Vyas VK. A patent review of human dihydroorotate dehydrogenase (hDHODH) inhibitors as anticancer agents and their other therapeutic applications (1999-2022). Recent Patents Anti-Cancer Drug Disc. 2023;19(3):280–297. doi: 10.2174/1574892818666230417094939
   Google Scholar
• Munier-Lehmann H, Vidalain P-O, Tangy F, et al. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013;56(8):3148–3167.
   PubMed Web of Science ®Google Scholar
• Azeredo LFSP, Coutinho JP, Jabor VAP, et al. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors. Eur J Med Chem. 2017;126:72–83. doi: 10.1016/j.ejmech.2016.09.073
   PubMed Web of Science ®Google Scholar
• Boschi D, Pippione AC, Sainas S, et al. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research. Eur J Med Chem. 2019;183:111681. doi: 10.1016/j.ejmech.2019.111681
   PubMed Web of Science ®Google Scholar
• Hoelz LV, Calil FA, Nonato MC, et al. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria. Future Med Chem. 2018;10(15):1853–1874.
   PubMed Web of Science ®Google Scholar
• Vyas VK, Shukla T, Tulsian K, et al. Integrated structure-guided computational design of novel substituted quinolizin-4-ones as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. Comput Biol Chem. 2022;101:107787. doi: 10.1016/j.compbiolchem.2022.107787
   PubMed Web of Science ®Google Scholar
• Baldwin J, Farajallah AM, Malmquist NA, et al. Malarial Dihydroorotate Dehydrogenase. J Biol Chem. 2002;277(44):41827–41834.
   PubMed Web of Science ®Google Scholar
• Belen Cassera M, Zhang Y, Hazleton K Z, et al. Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum. Curr Top Med Chem. 2011;11(16):2103–2115.
   PubMed Web of Science ®Google Scholar
• Krungkrai SR, Krungkrai J. Insights into the pyrimidine biosynthetic pathway of human malaria parasite Plasmodium falciparum as chemotherapeutic target. Asian Pac J Trop Med. 2016;9(6):525–534. doi: 10.1016/j.apjtm.2016.04.012
   PubMed Web of Science ®Google Scholar
• Roth A, Maher SP, Conway AJ, et al. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat Commun. 2018;9(1):1837.
   PubMedGoogle Scholar
• Alzain AA, Ahmed ZAM, Mahadi MA, et al. Identification of novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitors for malaria using in silico studies. Scientific African. 2022;16:e01214. doi: 10.1016/j.sciaf.2022.e01214
   Google Scholar
• Batt DG. Inhibitors of dihydroorotate dehydrogenase. Expert Opin Ther Patents. 1999;9(1):41–54. doi: 10.1517/13543776.9.1.41
   Web of Science ®Google Scholar
• Kumar S, Narasimhan B. Therapeutic potential of heterocyclic pyrimidine scaffolds. Chem Cent J. 2018;12(1):38. doi: 10.1186/s13065-018-0406-5
   PubMedGoogle Scholar
• Loffler M, Fairbanks L, Zameitat E, et al. Pyrimidine pathways in health and disease. Trends Mol Med. 2005;11(9):430–437. doi: 10.1016/j.molmed.2005.07.003
   PubMed Web of Science ®Google Scholar
• Sørensen P, Dandanell G. A new type of dihydroorotate dehydrogenase, type 1S, from the thermoacidophilic archaeon sulfolobus solfataricus Jun. Extremophiles. 2002;6(3):245–251. doi: 10.1007/s00792-001-0249-0
   PubMed Web of Science ®Google Scholar
• Lane AN, Fan T-M. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43(4):2466–2485. doi: 10.1093/nar/gkv047
   PubMed Web of Science ®Google Scholar
• Wang X, Yang K, Wu Q, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Sci, trans med. 2019;11(504). doi: 10.1126/scitranslmed.aau4972
   Web of Science ®Google Scholar
• Phillips M, Rathod PK, Baldwin JG. Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activityp. WO2007149211A1. 2007.
   Google Scholar
• Phillips M, Rathod PK, Baldwin JG. Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activityp. US20080027079A1. 2008.
   Google Scholar
• Phillips M, Rathod PK, Gujjar R, et al. Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activityp. WO2009082691A1. 2009.
   Google Scholar
• Phillips M, Rathod PK, Gujjar R, et al. Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activityp. US20090209557A1. 2009.
   Google Scholar
• Phillips M, Rathod PK, Gujjar R, et al. Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activityp. US9216983B2. 2015.
   Google Scholar
• Phillips M, Rathod PK, Charman SA, et al. Antimalarial agents that are inhibitors of dihydroorotate dehyrogenasep. WO2011041304A2. 2011.
   Google Scholar
• Rathod PK, Floyd D, Burrows J, et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. EP2483274B1. 2009.
   Google Scholar
• Rathod PK, Floyd D, Burrows J, et al. Antimalarial agents that are inhibitors of dihydroorotate dehydrogenasep. US20120302586A1. 2012.
   Google Scholar
• Rathod PK, Floyd D, Burrows J, et al. Antimalarial agents that are inhibitors of dihydroorotate dehyrogenasep. US9238653B2. 2016.
   Google Scholar
• Phillips M, Charman SA, Rathod PK, et al. New substituted triazolopyrimidines as anti-malarial agents. EP3072894A1. 2016.
   Google Scholar
• Phillips M, Charman SA, Rathod PK, et al. New substituted triazolopyrimidines as anti-malarial agentsp. WO2016151521A1. 2016.
   Google Scholar
• Phillips M, Charman SA, Rathod PK, et al. New substituted triazolopyrimidines as anti-malarial agentsp. US20180065968A1. 2018.
   Google Scholar
• Booker ML, Celatka CC, Clardy JC, et al. Small molecule inhibitors of plasmodium falciparum dihydroorotate dehyrogenase. WO2009137081A2. 2009; Cambridge (MA): Genzyme Corporation.
   Google Scholar
• Bastos C, Booker ML, Celatka CA, et al. Small molecule inhibitors of plasmodium falciparum dihydroorotate dehyrogenase. US8703811B2. 2014.
   Google Scholar
• Bastos C, Booker ML, Celatka CA, et al. Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenasep. US20110130381A1. 2011.
   Google Scholar
• Phillips M, Palmer M, Charman SA, et al. Anti-malarial agents. EP3842100A1. 2021.
   Google Scholar
• Phillips M, Palmer M, Charman SA, et al. Anti-malarial agentsp. WO2021123266A1. 2021.
   Google Scholar
• Phillips M, Palmer M, Charman SA, et al. Anti-malarial agents. US20230056202A1. 2023.
   Google Scholar
• Singh A, Maqbool M, Mobashir M, et al. Dihydroorotate dehydrogenase: a drug target for the development of antimalarials. Eur J Med Chem. 2017;125:640–651. doi: 10.1016/j.ejmech.2016.09.085
   PubMed Web of Science ®Google Scholar
• Barnett DS, Guy RK. Antimalarials in Development in 2014. Chem Rev. 2014;114(22):11221–11241. doi: 10.1021/cr500543f
   PubMed Web of Science ®Google Scholar
• Schrader FC, Barho M, Steiner I, et al. The antimalarial pipeline – An update. Int J Med Microbiol. 2012;302(4–5):165–171.
   PubMed Web of Science ®Google Scholar